Physician profile
Catherine Smith
NPI 1023608072
$5,069.02
in general payments reported to CMS, 2019-2025
24 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $698 · 2022: $1,825 · 2023: $714 · 2024: $611 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $971.70 | 2021-2025 | Lybalvi, Aristada |
| Corium, LLC | $565.36 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $559.01 | 2021-2023 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $371.91 | 2021-2023 | Austedo |
| Otsuka America Pharmaceutical, INC. | $351.17 | 2021-2025 | Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $280.02 | 2022-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $263.49 | 2025 | Jornay Pm |
| Abbvie INC. | $222.99 | 2021-2022 | |
| Lundbeck LLC | $195.07 | 2021-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $177.19 | 2021-2022 | |
| Tempus Ai, INC | $173.71 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Neos Therapeutics, Lp | $171.55 | 2024-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $134.23 | 2021-2025 | Trintellix |
| Indivior INC. | $122.64 | 2021-2023 | Perseris |
| Supernus Pharmaceuticals, INC. | $114.17 | 2025 | Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $82.96 | 2024-2025 | Onyda Xr |
| Ironshore Pharmaceuticals INC. | $79.93 | 2024 | |
| Noven Therapeutics, LLC | $58.87 | 2024-2025 | Xelstrym |
| Bausch Health US, LLC | $45.94 | 2022 | |
| Vanda Pharmaceuticals INC. | $35.52 | 2022 | |
| Neurocrine Biosciences, INC. | $32.48 | 2022-2023 | Ingrezza |
| Jazz Pharmaceuticals INC. | $22.85 | 2022 | |
| Adlon Therapeutics L.P. | $18.42 | 2021 | |
| Owp Pharmaceuticals, INC. | $17.84 | 2025 | Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.